EU warns Ireland over PI applications

18 April 2001

The European Commission has threatened to take the Republic of Irelandto the European Court of Justice over what it considers to be the unacceptably long times taken by the Irish authorities to approve parallel import applications for medicines.

The length of the procedures for these products, which average approximately two and a half years, constitute an illegal trade barrier, and the majority of them could be replaced by use of a simplified procedure, according to a reasoned opinion from the Commission. It has given the Irish government two months in which to produce a solution to the problem.

Meantime, the review which Ireland has requested by the Organization for Economic Cooperation and Development of its national regulatory practices and domestic regulatory reforms has now been completed and is due to be published on April 24.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight